COVID-19: FDA Authorizes Pharmacists to Prescribe PAXLOVID with Certain Limits
The FDA issued an emergency use authorization (EUA) for PAXLOVID (nirmatrelvir co-packaged with ritonavir) for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients at high risk for progression to severe COVID-19, including hospitalization or death. On July 6, the FDA revised the EUA to let pharmacists prescribe and dispense PAXLOVID to eligible patients without seeing a doctor or other clinician.
- New COVID-19 Treatments Add-On Payment (NCTAP) webpage (Note: You may need to refresh your browser if you recently visited this webpage)
- Fact Sheet for Health Care Providers: EUA for PAXLOVID: information about the limits and conditions